Infliximab in ulcerative colitis
Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). I...
Enregistré dans:
Auteurs principaux: | Avi Levin, Oren Shibolet |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2008
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d7d25d975b084e1b95110d58fe7dcd89 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
par: Bradley GM, et autres
Publié: (2012) -
Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
par: Viscido A, et autres
Publié: (2019) -
Golimumab in unresponsive ulcerative colitis
par: Lippert E, et autres
Publié: (2014) -
New and emerging treatments for ulcerative colitis: a focus on vedolizumab
par: Gledhill T, et autres
Publié: (2013) -
Infliximab for the treatment of plaque psoriasis
par: Jennifer S Gall, et autres
Publié: (2008)